US 11920132
Oligonucleotide therapy for Leber congenital amaurosis
granted A61KA61K31/7125A61P
Quick answer
US patent 11920132 (Oligonucleotide therapy for Leber congenital amaurosis) held by ProQR Therapeutics II B.V. expires Mon Feb 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- ProQR Therapeutics II B.V.
- Grant date
- Tue Mar 05 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Feb 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 2
- CPC classes
- A61K, A61K31/7125, A61P, A61P27/02